Mountain Pacific Investment Advisers Inc. ID Sells 25 Shares of Eli Lilly and Company (NYSE:LLY)

Mountain Pacific Investment Advisers Inc. ID trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 385 shares of the company’s stock after selling 25 shares during the quarter. Mountain Pacific Investment Advisers Inc. ID’s holdings in Eli Lilly and Company were worth $224,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Kovack Advisors Inc. lifted its position in shares of Eli Lilly and Company by 22.5% in the 4th quarter. Kovack Advisors Inc. now owns 4,751 shares of the company’s stock worth $2,769,000 after purchasing an additional 872 shares during the period. K.J. Harrison & Partners Inc purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $3,325,000. Boyd Watterson Asset Management LLC OH lifted its position in shares of Eli Lilly and Company by 12.4% in the 4th quarter. Boyd Watterson Asset Management LLC OH now owns 13,651 shares of the company’s stock worth $7,957,000 after purchasing an additional 1,510 shares during the period. Callan Capital LLC lifted its position in shares of Eli Lilly and Company by 169.6% in the 4th quarter. Callan Capital LLC now owns 2,828 shares of the company’s stock worth $1,648,000 after purchasing an additional 1,779 shares during the period. Finally, O Brien Greene & Co. Inc lifted its position in shares of Eli Lilly and Company by 3.9% in the 4th quarter. O Brien Greene & Co. Inc now owns 943 shares of the company’s stock worth $550,000 after purchasing an additional 35 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

LLY traded up $8.64 during midday trading on Friday, hitting $733.51. 2,009,249 shares of the company traded hands, compared to its average volume of 2,265,427. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.47, a PEG ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $380.77 and a 52-week high of $800.78. The business has a 50 day simple moving average of $761.79 and a two-hundred day simple moving average of $666.06.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $2.09 earnings per share. On average, equities analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of a number of analyst reports. Bank of America increased their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.